Know the Signs, Take Action: James Casey Birthday Benefit & Colorectal Cancer Awareness Initiative
From Music to Medicine: Continuing the Fight and Increasing Access
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / ABOUT: Charity auction and screening drive featuring exclusive, one-of-a-kind collectors items generously donated by artists like Trey Anastasio and Dave Matthews. Proceeds from the event will directly support colorectal cancer screening services for uninsured individuals via Fight Colorectal Cancer (Fight CRC), an organization helping to ensure that more people have access to early detection methods.
The Association of Black Gastroenterologists and Hepatologists (ABGH) will host a virtual webinar and screening drive in honor of Casey's life and legacy on Sunday, March 2 titled, 'Your Health, Your Voice: Knowing the Signs of Colorectal Cancer and Taking Action.' The event aims to have a real conversation about colorectal cancer trends and risks, especially among young people. ABGH thought leaders will discuss early screening options, disseminate resources and hold an interactive Q&A. The webinar is free and open to the public, and those in attendance can anonymously submit questions for the panel upon registration.
WHY: Colorectal cancer diagnoses are on the rise among young people and disproportionately among African Americans. Despite being one of the most preventable cancers, many individuals still lack access to critical screening services. Early detection is vital, as it significantly increases the chances of successful treatment and survival. By supporting this initiative, participants help bridge the gap in healthcare equity, provide life-saving resources to underserved communities, and honor James Casey's mission to raise awareness and inspire action in the fight against colorectal cancer.
WHEN:
HERE.
HERE.
'Because colon cancer is almost always treatable when caught early, James shared his story in hopes that others might avoid his fate,' his wife Ayla Casey shares. 'Thank you all for the continued support you've shown for James and this mission. We hope this initiative will make a positive impact on our community and amplify James' message as we celebrate his life, music and legacy.'
MORE
A longtime resident of New York City, James Casey was an established multi-instrumentalist, producer and vocalist. Widely known for his saxophone performances with Trey Anastasio Band, Meghan Trainor and members of the Grateful Dead like Phil Lesh & Friends and Billy and the Kids, James Casey recorded and released his first studio albums soon after learning of his late-stage cancer diagnosis in 2021. His Christmas album, A Little Something For Everyone, released in December 2022 and garnered praise on NPR Jazz Night in America's holiday playlist. Then, in between chemotherapy treatments, James Casey recorded and released 'New Bloom', the first single from his original solo debut album, The Kauai Project. 'New Bloom' and its poignant lyrics became a mantra for James Casey that year. The single landed on NPR Staff Picks for the 100 Best Songs of 2023 and its creation was shared in a segment on The Today Show. He released two more singles 'E.J.B.M.' and 'Outside' before his health took a turn. James Casey passed away from colorectal cancer at age 40 on August 28, 2023. One year later, The Kauai Project EP released posthumously and landed on first-round ballots for the 2025 Grammy nominations. While the album made his final mark on the music landscape, James Casey's legacy and advocacy lives on with those who continue to draw inspiration and insight from his incredible story.
To learn more about James Casey, his cancer battle and how it intersected with his musical journey, watch the docu-short Music As Medicine: A James Casey Story and visit his official website www.jamescaseysax.co for music, merch and more. James' story has previously been featured on Previously featured by The Today Show, The Atlantic's People V. Cancer, WNYC, and more.
The Association of Black Gastroenterologists and Hepatologists (ABGH) is a non-profit organization founded in 2021 by gastroenterologists and hepatologists from across America for the purpose of addressing healthcare disparities in gastrointestinal and liver diseases disproportionately affecting Black communities. Their work seeks to promote health equity among Black communities; advance science and develop the careers of Black gastroenterologists, hepatologists and scientists; and improve gastrointestinal health outcomes in Black communities through a network of support, resources and expert knowledge. Learn more at blackingastro.org.
Fight Colorectal Cancer (Fight CRC) is a leading patient-empowerment and advocacy organization in the United States, providing balanced and objective information on colon and rectal cancer research, treatment, and policy. We are relentless champions of hope, focused on funding promising, high-impact research endeavors while equipping advocates to influence legislation and policy for the collective good. Learn more at FightCRC.org.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Concerns raised around mental health care as MP calls for ‘urgent' action
A healthcare watchdog carried out an inspection of mental health wards for older people in Greater Manchester after receiving 'concerning information' from whistleblowers. Pennine Care NHS Foundation Trust provides mental health services across Greater Manchester, including units at Fairfield General Hospital, Birch Hill Hospital and Royal Oldham Hospital. It was assessed by the Quality Care Commission (CQC) in November last year in response to 'concerning information' received about several mental health wards from complaints, whistleblowing concerns and notifications from the trust. The assessment included onsite inspections of all nine of the trust's wards. The report, which was published in May, found five breaches of regulations and highlighted concerns around staffing, patient care and training. Inspectors found that patients did not always receive "sufficient person-centred support to make their own decisions". Get the latest news delivered straight to your inbox by signing up to the Bury Times morning newsletter as well as our breaking news alerts. The report said that patients who were unable to clearly communicate their needs verbally "did not have communication care plans or any planned individualised support to support them in making and communicating decisions about their care". For patients who might have impaired mental capacity, staff "did not always assess and record capacity to consent appropriately". It added that relatives and carers "mostly gave positive feedback" but that some reported that they were "only allowed an hour with their relatives". Inspectors found that it was "not possible" to identify the proportion of staff on each ward who had completed Mental Health Act awareness training or how up to date this was due to it not being compulsory. The service "did not have effective arrangements to monitor adherence to the Mental Capacity Act" at the time of the visit and the trust was not carrying out regular audits to ensure that the Mental Health Act was being applied correctly. The report found that although the wards were "usually staffed to safe levels", there was "high use" of temporary staff to cover vacancies, staff sickness and enhanced clinical need on the wards. It also shared that the systems for induction and training of temporary staff "did not always ensure that staff were familiar with the wards and the needs of the patients they were caring for". READ NEXT: Eight Bury schools set to receive share of £54m funding for essential work READ NEXT: Greater Manchester to get £2.5bn transport boost- including new Bury tram stop While "most" patients told inspectors that the food was "good", some said that "good quality food which met their cultural needs was not always available" and that they did not have access to spiritual support on the ward when they "would have liked this". The CQC has instructed the trust to provide an action plan and to make improvements in response to the concerns found. Bury North MP James Frith deemed the findings 'unacceptable' and has written to the trust's chief executive demanding 'urgent answers and action' along with an immediate meeting. The Labour MP said: 'The CQC's findings are deeply troubling. "Older people in Bury deserve far better than wards that fall short on safety, staffing, and care. 'Since sharing my letter, I've been contacted by families of patients who've come forward with their own experiences – adding weight to the serious concerns raised. 'I've written to the trust demanding urgent improvements to ensure dignity, safety, and proper treatment for some of our most vulnerable residents.' The trust also provides mental health services for military veterans across Greater Manchester. The overall rating of the trust's wards for older people with mental health needs has dropped from its former "good" status to "requires improvement". READ NEXT: Up to 120 taxi drivers in Bury face 'immediate suspension' READ NEXT: Work to start on replacement for bridge destroyed a decade ago Tim McDougall, executive director of quality, nursing and healthcare professionals at Pennine Care NHS, said: 'We accept the findings of the CQC's assessment of our older adult mental health wards and are fully committed to addressing the areas identified for improvement. 'Our focus is on delivering high-quality, person-centred care for all our patients. 'While the inspection highlighted challenges, it also recognised positive practice - the compassionate care of staff, clean and safe ward environments, and our culture of safety and openness. 'We are already delivering a robust improvement plan focused on strengthening clinical standards, patient engagement, staff training and ward leadership. 'We're also improving compliance with mental health law, access to therapeutic activities and work to further embed a culture of kindness, respect and safety. 'Importantly, we are working in partnership with patients, carers and staff to ensure lasting change. 'We're proud our efforts are reflected in our latest NHS Staff Survey results which showed improvements across all seven themes, scores above the national average, and recognition as the best mental health and learning disability trust to work for in the North.'
Yahoo
2 days ago
- Yahoo
First Ascent Biomedical and Fight Colorectal Cancer Announce Groundbreaking Study to Advance Precision Oncology for Colorectal Cancer Patients
Springfield, Mo., June 06, 2025 (GLOBE NEWSWIRE) -- First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine, is proud to announce a new collaboration with national nonprofit Fight Colorectal Cancer (Fight CRC) to launch a prospective feasibility study aimed at transforming colorectal cancer treatment. Funded by a $350,000 grant from Fight CRC, and spearheaded by Anjee Davis, chief executive officer, this innovative study will leverage First Ascent's cutting-edge xDRIVE tumor profiling technology to deliver rapid, personalized treatment insights for patients fighting colon cancer in Minnesota. 'Fight CRC is committed to empowering patients through innovation,' said Davis. 'This grant underscores our strategic focus on enhancing care through advanced research, particularly for those with limited treatment options.' The study, set to begin enrollment in April or May 2025, will focus on 25 patients with metastatic colorectal cancer. By integrating functional drug testing, genetic analysis, and artificial intelligence, First Ascent's xDRIVE platform will provide oncologists with detailed tumor profiling data and tailored treatment options, aiming to enhance patient outcomes. Leading the clinical efforts are Hao Xie, MD, PhD, a gastrointestinal cancer specialist and precision medicine expert, and Dr. Boardman, whose work in cancer genetics and early detection has advanced the field of colorectal cancer care. Noah Berlow, PhD, First Ascent's Chief Technology Officer and the study's principal investigator, brings his expertise in AI-driven cancer research to oversee the project. Together, this team is poised to demonstrate the power of rapid, individualized tumor profiling to better understand each patient's unique cancer. 'This collaboration with Fight Colorectal Cancer is another important step in transforming how we approach cancer treatment,' said Jim Foote, founder and chief executive officer, First Ascent Biomedical. 'We are honored to be part of this effort.' The study is expected to complete enrollment within nine months and will provide actionable data to oncologists for patients requiring advanced treatment options. Patients interested in participating must be seen in Rochester, MN. Information will soon be available on CONTACT: Savanna Doud Fight Colorectal Cancer 703.548.1225 savanna@ in to access your portfolio
Indianapolis Star
2 days ago
- Indianapolis Star
Moderna Announces Update on Investigational Pandemic Influenza Program
Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype. The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines. 'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.' The Phase 1/2 study evaluated a two-dose regimen of Moderna's investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response. At baseline, pre-existing immunity was minimal, with only 2.1% of participants showing hemagglutination inhibition (HAI) antibody titers ≥1:40, an HAI titer considered to correlate with protection. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved titers ≥1:40 with a 44.5-fold increase of titers from baseline. The investigational vaccine was generally well-tolerated, with no dose-limiting tolerability concerns observed. Most solicited adverse reactions were Grade 1 or 2 and did not increase significantly with number of doses or between first and second doses. Further data is expected to be submitted for presentation at an upcoming scientific meeting. Moderna will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the Company's strategic commitment to pandemic preparedness. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the clinical development of mRNA-1018, the safety and immunogenicity data from the Phase 1/2 study; the cancellation of the development contract for Moderna's pandemic flu program by the U.S. Department of Health and Human Services; and the exploration of alternative paths for development of the vaccine program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire
